Phase II Study of Arsenic Trioxide in Patients With Multiple Myeloma
Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
Phase II trial to study the effectiveness of arsenic trioxide in treating patients
who have relapsed or refractory stage II or stage III multiple myeloma.
Study Status: Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
Drug: arsenic trioxide
Information provided by:
National Cancer Institute (NCI)
Study Type: Interventional
Study Design: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
Carolyn Paradise, MD., Study Chair